Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director | March 31, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Skye Bioscience, Inc.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2036-03-31 | Direct | 75,000 |
Reported balance
After 2026-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 75,000 · Balance 75,000 F1: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 22:17 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001628280-26-023349 · wk-form4_1775168222.xml · derivative · entry 1 Charych Deborah H. · CIK 0001965700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 01:54 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001628280-26-006622 · wk-form4_1770688470.xml · derivative · entry 1 Charych Deborah H. · CIK 0001965700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-02-06 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 22:41 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0001516551-25-000008 · wk-form4_1740609698.xml · derivative · entry 1 Charych Deborah H. · CIK 0001965700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning February 21, 2025. Read SEC document |
| October 28, 2024 Filed Oct 31, 2024 00:25 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $5.15 | $0.00 |
DisclosureSEC source: 0001516551-24-000097 · wk-form4_1730334350.xml · derivative · entry 1 Charych Deborah H. · CIK 0001965700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-10-27 F1 · derivative.exercise_date: The stock option vests in equal monthly installments over the one year period beginning October 28, 2024. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:02 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001516551-24-000039 · wk-form4_1709593294.xml · derivative · entry 1 Charych Deborah H. · CIK 0001965700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the one year period beginning February 29, 2024. Read SEC document |
| November 06, 2023 Filed Nov 7, 2023 01:30 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 14,110 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001516551-23-000097 · wk-form4_1699320601.xml · derivative · entry 1 Charych Deborah H. · CIK 0001965700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,001 Underlying: Common Stock · 14,110 shares Expires 2033-08-25 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $3.50 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 22:02 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 1,472,692 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001516551-23-000054 · wk-form4_1693346510.xml · derivative · entry 1 Charych Deborah H. · CIK 0001965700 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,472,692 Underlying: Common Stock · 1,472,692 shares Expires 2033-08-25 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.014 per option share for ten years from August 25, 2023 and the options will vest in equal monthly installments over the one year period beginning August 24, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 22:30 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001516551-23-000022 · wf-form4_167658660353462.xml · derivative · entry 1 Charych Deborah H. · CIK 0001965700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-02-14 F1 · derivative.exercise_date: 1. The option grant shall be exercisable for a price of $0.039 per option share for ten years from February 14, 2023 and the options will vest in equal monthly installments over the one year period beginning February 15, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.